In vitro activity of ceftizoxime, ceftazidime, cefuroxime, ceftriaxone, cefotaxime, and penicillin against Streptococcus pneumoniae as determined by three quantitative methods

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 15, Issue 4, 1996, Pages 344-346

  Barry, A L ^a   Brown, S D ^a   Fuchs, P C ^a  

^a CLINICAL MICROBIOLOGY INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ANTIBIOTIC AGENT; CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; OXACILLIN; PENICILLIN G;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DILUTION; DRUG POTENCY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

CEFOTAXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORINS; MICROBIAL SENSITIVITY TESTS; PENICILLINS; STREPTOCOCCUS PNEUMONIAE;

EID: 0029951511     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01695670     Document Type: Article

References (14)

1. Baquero, F: Pneumococcal resistance to β-lactam antibiotics: a global geographic overview. Microbial Drug Resistance 1995, 1: 115-120.
2. Breiman RF, Butler JC, Tenover FC, Elliot JA, Facklam RR: Emergence of drug-resistant pneumococcal infections in the United States. Journal of the American Medical Association 1994, 271: 1831-1835.
3. Chandy JC: Treatment failure with use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: case report and review. Clinical Infectious Diseases 1994, 18: 188-193.
4. Jacobs MR: Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae. Clinical Infectious Diseases 1992, 15: 119-127.
5. Haas DW, Stratton CW, Griffin JP, Weeks L, Alls SC: Diminished activity of ceftizoxime in comparison to cefotaxime and ceftriaxone against Streptococcus pneumoniae. Clinical Infectious Diseases 1995, 20: 671-676.
6. Stratton CW, Aldridge KE, Gelfand MS: In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels. Diagnostic Microbiology and Infectious Disease 1995, 22: 35-42.
7. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A5, NCCLS, Wayne, PA, 1993.
8. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A3, NCCLS, Wayne, PA, 1993.
9. Swenson JM, Hill BC, Thornsberry C: Screening pneumococci for penicillin resistance. Journal of Clinical Microbiology 1986, 24: 749-752.
10. Jorgensen JH, Swenson JM, Tenover FC, Ferraro MJ, Hindler JA, Murray PR: Development of interpretive criteria and quality control limits for broth microdilution and disk diffusion antimicrobial susceptibility testing of Streptococcus pneumoniae. Journal of Clinical Microbiology 1994, 32: 2448-2459.
11. Jorgensen JH, Ferraro MJ, McElmeel ML, Spargo J, Swenson JM, Tenover FC: Detection of penicillin and extended spectrum cephalosporin resistance among Streptococcus pneumoniae clinical isolates by use of the E-test. Journal of Clinical Microbiology 1994, 32: 159-163.
12. Linares J, Alonso T, Perez JL, Ayats J, Dominquez MA, Pallares R, Martin R: Decreased susceptibility of penicillin-resistant pneumococci to twenty-four β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 1992, 30: 279-288.
13. Barry AL, Pfaller MA, Fuchs PC, Packer RR: In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. medical centers in 1992 and 1993. Antimicrobial Agents and Chemotherapy 1994, 38: 2419-2425.
14. Thornsberry C, Brown SD, Yee YC, Bouchillon SK, Marier JK, Rich T: Increasing penicillin resistance in Streptococcus pneumoniae in the U.S.: effect on susceptibility to oral cephalosporins. Infections in Medicine 1993, Special Supplement: 15-24.